Roche

Actualités

Reuters - Il y a 2 semaines

Roche’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions

BRIEF-Roche’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions May 17 (Reuters) - Roche Holding AG ROG.S : ROCHE’S BTK INHIBITOR FENEBRUTINIB SIGNIFICANTLY REDUCED BRAIN LESIONS IN PEOPLE WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS Source text for Eikon: ID:nGNE5j1VXl Further company coverage: ROG.S (Gdansk Newsroom)

Reuters - Il y a 2 semaines

Column: Despite Trump pardon, ex-InterMune CEO owes millions in legal fees, Delaware judge finds

Column: Despite Trump pardon, ex-InterMune CEO owes millions in legal fees, Delaware judge finds By Alison Frankel May 11 (Reuters) - (The opinions expressed here are those of the author, a columnist for Reuters.) Scott Harkonen, the onetime CEO of biotech company InterMune Inc, spared no expense when he was indicted in 2008 for wire fraud based on what prosecutors said was a deceptive press release in 2002 about clinical trial results for an InterMune drug.

Reuters - Il y a 3 semaines

Bayer sees 2023 results at lower end of range as weedkiller prices drop

UPDATE 3-Bayer sees 2023 results at lower end of range as weedkiller prices drop Adds background on CEO-designate, details on shares and analyst comment from fourth paragraph By Ludwig Burger FRANKFURT, May 11 (Reuters) - Drug and pesticide maker Bayer BAYGn.DE said its 2023 results would likely come in at the lower end of its targeted range, hurt by cost inflation and a slump in prices of glyphosate-based weedkillers from last year's highs.

Reuters - Il y a 3 semaines

BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit

UPDATE 1-BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit Adds details on treatment, more on Nature readout FRANKFURT, May 10 (Reuters) - Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech 22UAy.DE potentially bodes well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients.

Reuters - Il y a 3 semaines

BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit

BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit FRANKFURT, May 10 (Reuters) - Scientific journal Nature on Wednesday said a personalised treatment based on messenger RNA by BioNTech 22UAy.DE was boding well for the future of fighting an extremely aggressive form of cancer after the regimen was shown to trigger a promising immune reaction in some pancreatic cancer patients.

Reuters - Il y a 3 semaines

Roche: FDA Accepts Application For Vabysmo

BRIEF-Roche: FDA Accepts Application For Vabysmo May 9 (Reuters) - Roche Holding Ag ROG.S : FDA ACCEPTS APPLICATION FOR ROCHE’S VABYSMO FOR THE TREATMENT OF RETINAL VEIN OCCLUSION (RVO) FDA ACCEPTS APPLICATION FOR ROCHE’S VABYSMO FOR THE TREATMENT OF RETINAL VEIN OCCLUSION (RVO) ACCEPTANCE BASED ON TWO PHASE III STUDIES THAT DEMONSTRATED EARLY

Reuters - Il y a 4 semaines

ImmunoGen surges after cancer drug study hits a 'home run'

ImmunoGen surges after cancer drug study hits a 'home run' May 3 (Reuters) - ImmunoGen Inc IMGN.O shares more than doubled on Wednesday after the company said its experimental ovarian cancer drug helped extend the lives of patients in a late-stage trial. The biotech company said the drug candidate, Elahere, also significantly prolonged the time that a patient lives without the cancer worsening, when compared with chemotherapy.

Reuters - Il y a 4 semaines

Investors see big Novo Nordisk stock boost if obesity drug shows heart benefit

ANALYSIS-Investors see big Novo Nordisk stock boost if obesity drug shows heart benefit Demand is soaring for Novo's weight-loss drug Wegovy Trial tests if Wegovy also has heart benefits Positive trial data could widen insurance coverage Wegovy only available so far in U.S., Denmark and Norway Trial readout expected between June and August By Maggie Fick LONDON, May 3 (Reuters) - Positive trial data showing Novo Nordisk’s obesity drug helps save and extend lives, not just lose weight, could pr

Reuters - Il y a 4 semaines

Earlysign Expands Collaboration With Roche In Supporting Early Detection Of Colon Cancer

BRIEF-Earlysign Expands Collaboration With Roche In Supporting Early Detection Of Colon Cancer May 1 (Reuters) - Medial EarlySign : EARLYSIGN EXPANDS COLLABORATION WITH ROCHE IN SUPPORTING EARLY DETECTION OF COLON CANCER Source text for Eikon: ID:nPnbfQpHLa Further company coverage: ROG.S

Reuters - Il y a 4 semaines

European shares end April with gains as earnings boost outweighs bank slide

UPDATE 2-European shares end April with gains as earnings boost outweighs bank slide For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 ends April 1.9% higher Defensive real estate, healthcare top monthly gainers Miners, tech sectors biggest decliners in April NatWest down on deposit outflows Electrolux top STOXX gainer on better Q1 print Adds comments, details, updates prices throughout By Shreyashi Sanyal April 28 (Reuters) - Eu

Reuters - Il y a 4 semaines

Bayer chair faces 'No' vote from largest German mutual funds

UPDATE 2-Bayer chair faces 'No' vote from largest German mutual funds Adds investor views and comments By Patricia Weiss and Ludwig Burger FRANKFURT, April 28 (Reuters) - Germany's three biggest asset management groups said they would not vote for the re-election of Bayer BAYGn.DE Chairman Norbert Winkeljohann on Friday because of his numerous board commitments.

Reuters - Il y a 4 semaines

Bayer chair faces "no" vote from largest German mutual funds

Bayer chair faces "no" vote from largest German mutual funds By Patricia Weiss and Ludwig Burger FRANKFURT, April 28 (Reuters) - Germany's three largest asset management groups on Friday said the would not vote for the re-election of Bayer BAYGn.DE Chairman Norbert Winkeljohann because of his numerous board commitments. An ouster of Winkeljohann, who won wide investor praise for winning former Roche executive Bill Anderson as Bayer's CEO-designate, could add to upheaval at the company, which has

Reuters - Il y a 4 semaines

Bristol Myers looks to new CEO as competition from generic drugs heats up

UPDATE 1-Bristol Myers looks to new CEO as competition from generic drugs heats up Rewrites with CEO change By Michael Erman April 27 (Reuters) - Bristol Myers Squibb BMY.N said on Wednesday evening its CEO Giovanni Caforio would step down in November and will be replaced by current Chief Commercialization Officer Chris Boerner, as the drugmaker contends with increasing generic competition for its top-selling drugs.

Reuters - Il y a 1 mois

Bristol Myers CEO Caforio to step down

UPDATE 2-Bristol Myers CEO Caforio to step down Adds executives' quotes, background April 26 (Reuters) - Bristol Myers Squibb Co BMY.N said on Wednesday CEO Giovanni Caforio will step down in November and be succeeded by Chief Commercialization Officer Christopher Boerner. Boerner, who has been CCO since 2018, was named chief operating officer until he takes the top job .

Reuters - Il y a 1 mois

Bristol Myers CEO Caforio steps down

CORRECTED-UPDATE 1-Bristol Myers CEO Caforio steps down Corrects designation of Boerner in paragraph 2 April 26 (Reuters) - Bristol Myers Squibb Co BMY.N said on Wednesday CEO Giovanni Caforio, who has been in the role since 2015, has decided to step down from his position. Chief Commercialization Officer Christopher Boerner will take up the role from Nov.

Reuters - Il y a 1 mois

Bristol Myers CEO Caforio steps down

CORRECTED-Bristol Myers CEO Caforio steps down Corrects designation of Boerner in paragraph 2 April 26 (Reuters) - Bristol-Myers Squibb Co BMY.N said on Wednesday CEO Giovanni Caforio, who has been in the role since 2015, has decided to step down from his position. Chief Commercialization Officer Christopher Boerner will take up the role from Nov. 1. He was previously head of international markets and has served in leadership roles at Seattle Genetics Inc and Roche's Genentech among others.

Reuters - Il y a 1 mois

Roche Says CHMP Recommends EU Approval Of Co's Fixed-Duration Columvi (Glofitamab)

BRIEF-Roche Says CHMP Recommends EU Approval Of Co's Fixed-Duration Columvi (Glofitamab) April 26 (Reuters) - Roche Holding Ag ROG.S : CHMP RECOMMENDS EU APPROVAL OF ROCHE’S FIXED-DURATION COLUMVI (GLOFITAMAB) FOR PEOPLE WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA RECOMMENDATION IS BASED ON RESULTS FROM THE PHASE I/II NP30179 STUDY

Reuters - Il y a 1 mois

Roche Q1 sales decline tempered by swift uptake of new eye drug

UPDATE 3-Roche Q1 sales decline tempered by swift uptake of new eye drug Q1 sales down 7% at 15.3 bln francs but above market view CEO says 432 mln francs in Vabysmo sales well above consensus 2023 core EPS decline still seen in "low single-digit" % range Roche repeats COVID related sales will drop by 5 bln francs Adds shares, fund manager comment By Ludwig Burger April 26 (Reuters) - Switzerland's Roche ROG.S said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and t

Reuters - Il y a 1 mois

Roche Q1 sales down 7% as related business wanes

Roche Q1 sales down 7% as COVID-related business wanes April 26 (Reuters) - Swiss drugmaker Roche ROG.S said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and diagnostics kits. Quarterly group revenue fell to 15.3 billion Swiss francs ($17.2 billion), the company reported on Wednesday, beating market expectations of 14.8 billion francs.

Reuters - Il y a 1 mois

Swiss stocks - Factors to watch on April 26

Swiss stocks - Factors to watch on April 26 ZURICH/BERLIN, April 26 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: COMPANY STATEMENTS ROCHE HOLDING AG ROG.S - Q1 results due at 0600 GMT ANALYSTS' VIEWS TEMENOS AG TEMN.S: JP MORGAN CUTS TARGET PRICE TO CHF 76 FROM CHF 79 EX-DIVIDEND FLUGHAFEN ZUERICH FHZN.S - CHF 3.50/share dividend ECONOMY Swiss April Investor Sentiment due at 0900 GMT.

Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Roche

Actualités

Conditions

Actifs populaires

Chat en direct XM